Cosmetic cross-reference Noindex: medium evidence

Glaucine

CAS 475-81-0

Glaucine (CAS 475-81-0) is a pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
2
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Glaucine
CAS Number
475-81-0
UNII
NU19306XA7
InChIKey
RUZIUYOSRDWYQF-HNNXBMFYSA-N
ChEMBL ID
CHEMBL228082
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- IC50 55482 nM 10 -
- Ki 1036.625 nM 8 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Glaucine used for in pharmaceutical contexts?

Glaucine (CAS 475-81-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Glaucine?

No adverse-event association or SIDER side-effect rows are rendered for Glaucine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Glaucine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Glaucine with EU status "permitted".

What clinical phase is Glaucine in?

No phase 1-4 clinical development badge is rendered for Glaucine because the matched compound identifier rows do not contain a max-phase value.